Written for a composite rural practice, the NU553 Unit 9 policy paper sets out DEA schedules and registration, then state rules left as State placeholders, then the clinic's own procedures. Searches like "nu 553 unit 9 assignment example", "nu553 unit 9 sample" and "nu553 unit 9 example" land here.
A First Controlled Substance Policy for a Two-Clinician Rural Practice: Federal Rules Stated, State Rules Left to Look Up
[Student Name]
Purdue University Global
NU553: Advanced Pharmacology and Pharmacotherapeutics
Unit 9 Policy Paper
[Instructor Name]
[Date]
The practice is a composite; state requirements are bracketed placeholders, and the paper is not legal advice.
Purpose and Scope
This policy governs the prescribing of controlled substances by clinicians at [Practice Name], with a focus on opioids for chronic pain in adults. It does not cover acute pain after procedures, cancer pain, palliative care or the treatment of opioid use disorder except where noted. Each federal requirement below is stated as a fact with its source, because it applies in every state; each state requirement is left as a placeholder, because it varies and a guess would be worse than a blank.
Section 1: Registration and Schedules
Policy. Every clinician who prescribes controlled substances from Schedules II through V holds a current DEA registration for the state in which the prescribing occurs, and a separate registration for each state in which they practice (21 C.F.R. § 1301.12, 2024).
Rationale. The Controlled Substances Act of 1970 places drugs into five schedules according to their accepted medical use and potential for abuse and dependence (21 U.S.C. § 812, 2024). Schedule I drugs have no accepted medical use. Schedule II includes most opioid analgesics, such as oxycodone, hydrocodone combination products and morphine, and carries the tightest controls. Registration ties each prescription to an accountable prescriber and location, which lets the DEA trace diversion and allows pharmacies to verify authority.
Section 2: What Federal Rules Add for Schedule II
Policy. Schedule II prescriptions are never written with refills. When a clinician judges it appropriate, several separate Schedule II prescriptions may be issued on the same day, each dated that day with the earliest date it may be filled written on it, together covering up to a 90-day supply (21 C.F.R. § 1306.12, 2024).
Rationale. The prohibition on refills forces a new decision, and usually a new contact, for each supply of the drugs most often misused. The 2007 option for multiple prescriptions reduces the burden of monthly visits for stable patients without abandoning the no-refill principle, since each prescription remains separate and dated. It does not require that stable patients receive 90 days at once; this practice will use it only for patients who have been stable for at least [composite] months and have a current treatment agreement.
Section 3: State Requirements, to Be Completed
The following requirements vary by state and are left as placeholders. For each, the source to consult is named.
1. [State] nurse practitioner prescriptive authority for each schedule, including whether Schedule II prescribing is permitted and under what limits. Source: the [State] Board of Nursing and the nurse practice act.
2. [State] collaboration or supervision requirements for nurse practitioner prescribing of controlled substances, and whether a written agreement must name them. Source: the [State] Board of Nursing.
3. [State] rules on checking the prescription drug monitoring program: before a first prescription, at intervals, or at every prescription, and for which schedules. Source: the [State] PDMP statute and the agency that operates it.
4. [State] limits on the days' supply or dose of a first opioid prescription for acute pain. Source: [State] statute or Board rule.
5. [State] requirements for electronic prescribing of controlled substances, and permitted exceptions. Source: [State] Board of Pharmacy.
6. [State] continuing education requirements on pain management or opioid prescribing. Source: the [State] Board of Nursing.
Rationale. A practice policy that states a state rule incorrectly is more dangerous than one that leaves it blank, because staff will follow it. The practice owner will review this section with the completed entries before the policy takes effect.
Section 4: Clinic Procedure for Opioids in Chronic Pain
Policy 4.1, before starting. Nonopioid therapies, both drug and nondrug, are tried or considered first. Before an opioid is started for chronic pain, the clinician documents the diagnosis, the functional goals, the benefits and risks discussed, and a plan for what happens if the goals are not met.
Rationale. The 2022 CDC guideline, which is clinical guidance and not law, recommends that nonopioid therapies be maximized and that opioids be considered only if expected benefits for pain and function outweigh risks (Dowell et al., 2022). Documented functional goals give the clinician and patient a shared measure of whether the drug is working.
Policy 4.2, starting doses. When an opioid is started, it is an immediate-release formulation at the lowest effective dose. Doses are increased cautiously, and the clinician reassesses benefit and risk before increasing to higher daily morphine milligram equivalents.
Rationale. Risk of overdose rises with dose, and extended-release formulations carry more risk at initiation (Dowell et al., 2022).
Policy 4.3, treatment agreement. Every patient receiving opioids for chronic pain for more than [composite] weeks has a signed treatment agreement covering one prescriber, one pharmacy, how refills and lost prescriptions are handled, urine drug testing and safe storage.
Rationale. The agreement is a communication tool, not a contract of distrust. It makes expectations explicit and prevents disputes from being improvised at the counter.
Policy 4.4, urine drug testing. Urine drug testing is used as a clinical tool at the start of treatment and at least [composite] times a year thereafter. Unexpected results are discussed with the patient and confirmed before any change in treatment.
Rationale. The CDC guideline presents testing as a way to inform care, not to punish, and advises against dismissing patients on the basis of a single result (Dowell et al., 2022).
Policy 4.5, naloxone. Naloxone is offered with every opioid prescription for chronic pain, and to patients with higher overdose risk, such as those taking benzodiazepines or at higher doses.
Rationale. Naloxone reverses opioid overdose and can be given by a family member, and offering it treats overdose as a risk to manage rather than an accusation.
Policy 4.6, storage and disposal. Every patient is taught to store opioids locked and out of reach of others and to dispose of unused tablets through a take-back site or approved method.
Rationale. Many people who misuse prescription opioids obtain them from a relative or friend, often from an unsecured supply at home.
Policy 4.7, reassessment. Patients on opioids for chronic pain are reassessed at least every [composite] months, with the PDMP checked as [State] requires, and a plan to taper if benefit is not maintained. Tapering is gradual and collaborative, never abrupt, except for safety emergencies.
Section 5: Two Federal Changes of 2023
Two federal changes took effect in 2023 and apply to this practice regardless of state. First, the Consolidated Appropriations Act, 2023, ended the separate federal waiver once needed before a clinician could treat opioid addiction with buprenorphine, so a prescriber registered for Schedule III drugs may now offer it, subject to state law, under Public Law 117-328. Second, the same law created a one-time training requirement: new and renewing DEA registrants must attest to having completed eight hours of training in the care of people with substance use disorders, opioid use disorder included. This practice will record each clinician's attestation date.
Rationale. The first change means that a patient in this practice who develops opioid use disorder can be offered treatment on site rather than referred to a distant specialist, which matters in a rural county. The second ensures every prescriber has baseline training in recognizing and treating that disorder.
Review
This policy will be reviewed annually and whenever federal or [State] law changes. The date of each review is recorded below.
References
21 C.F.R. § 1301.12 (2024). https://www.ecfr.gov/current/title-21/section-1301.12
21 C.F.R. § 1306.12 (2024). https://www.ecfr.gov/current/title-21/section-1306.12
Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, 136 Stat. 4459 (2022).
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC clinical practice guideline for prescribing opioids for pain: United States, 2022. MMWR Recommendations and Reports, 71(3), 1-95. https://doi.org/10.15585/mmwr.rr7103a1
21 U.S.C. § 812 (2024).
How this NU553 Unit 9 example is structured
The paper's organizing principle is jurisdiction. Federal requirements are stated as facts with citations because they apply in every state; state requirements are left as bracketed placeholders because they vary, and the paper names where each answer would be found rather than guessing it. That split is typically what graders look for first. Each policy statement has a rationale beneath it, linking the rule to the harm it addresses, so the policy reads as reasoning and not as a checklist copied from a template. Clinical guidance is dated: the 2022 CDC guideline on opioids for pain is cited for starting doses, reassessment and naloxone, and described as guidance rather than law. A final section addresses the two federal changes of 2023, the removal of the separate buprenorphine waiver and the one-time training requirement for DEA registrants.
Get an NU553 Unit 9 example written to your instructions
Include the State your NU553 Unit 9 prompt specifies, or say that it leaves the choice open, along with the drug classes involved and the rubric. At no cost for a first request and within 24-48h, the sample policy separates federal facts from state placeholders, dates every rule and puts a rationale beneath each one. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU553 Unit 9 questions, answered
Can the paper assume the rules of the state where I plan to practice?
Yes, where the prompt leaves the state open, but name it and cite the nursing board rule or statute behind every state-level requirement. The sample leaves State as a placeholder because authority over Schedule II drugs, collaboration terms and monitoring database requirements vary widely. A paper that picks a state and documents it is stronger than one that implies a national standard.
Is the CDC opioid guideline legally binding?
No. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is voluntary clinical guidance, and the document itself says it should not be applied as inflexible policy. Some states have written their own limits into law, which are binding. The stronger papers keep the two categories apart and cite each accordingly.
Should the policy cover stimulants and benzodiazepines too?
That depends on the prompt. The sample focuses on opioids for chronic pain because the case does, but the same structure, federal rule, state placeholder and clinic procedure, works for any scheduled class. Benzodiazepines are Schedule IV and most stimulants Schedule II, so the refill rules differ, and a broader policy should say so class by class.